(a, b) In vitro GUV experiments showing an increase of IRSp53 I-BAR binding on GUV upon HIV-1 Gag addition. (a) Representative confocal images of AX488 labeled IRSp53 I-BAR and AX546 labeled Gag on GUV membranes in ‘I-BAR + Gag’ condition. (b) Measurement of AX488 IRSp53 I-BAR fluorescence intensity on membranes in the absence of Gag (named ‘I-BAR only’), in the presence of Gag where GUVs were first incubated with IRSp53 I-BAR domain and then with HIV-1 Gag (named ‘I-BAR + Gag’). Each circle presents one GUV analysis. N = 27 GUVs, n = 2 sample preparations for ‘I-BAR only,’ N = 32 GUVs, n = 2 sample preparations for ‘I-BAR + Gag.’ To pool all data points from the two sample preparations, I-BAR intensities were normalized by the mean I-BAR intensity in the ‘I-BAR only’ condition. Protein bulk concentrations: 0.05 µM for I-BAR domain and 0.3 µM for Gag. **p=0.01133, Student’s t-test. (c, d) In vitro GUV experiments. (c) Representative confocal images of a GUV (the membrane contains 0.5 mol% of BODIPY-TR-C5-ceramide, red) incubating with a low concentration of IRSp53-I-BAR domain (0.05 μM, composed of 70% of unlabeled I-BAR domain and 30% of AX488 labeled I-BAR domain, green). The I-BAR domain induces membrane tubulation toward the interior of the GUV. (d) Representative confocal images of a GUV first incubated with IRSp53 I-BAR domain (0.05 μM, unlabeled), followed by addition of HIV-1 Gag (0.3 μM, AX488 labeled, green). GUV membranes contained 0.5 mol% of BODIPY-TR-C5-ceramide (red). The white arrow points to the accumulation of AX488 Gag singles at the tip of an I-BAR induced tube. Scale bars, = 5 µm. GUV, giant unilamellar vesicle.